Crawford Investment Counsel’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-23
Closed 294
2020
Q4
$0 Buy
+23
New +$49 ﹤0.01% 286

Other funds holding BMY.RT

Crawford Investment Counsel's BMY.RT Position: Q1 2021 in Review

Crawford Investment Counsel sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 23 shares.

Crawford Investment Counsel first reported a position in BMY.RT in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Crawford Investment Counsel reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Crawford Investment Counsel sold 23 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
  • Crawford Investment Counsel first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2020 and held it in 1 quarter.
  • Crawford Investment Counsel's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $0 in Q4 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Crawford Investment Counsel's 13F filing for Q1 2021, filed 14 May 2021.